Introduction
Melanoma has several features, which distinguish it from other cancers, most notably the fact that it is resistant to chemotherapy and radiation therapy. The response rate of patients with metastatic melanoma to systemic single-agent cytotoxic or biological therapy is less than 15%, and neither has demonstrated to benefit overall survival (Tsao et al., 2004) . To determine why melanoma is refractory to conventional therapy requires not only a better understanding of tumor -host immune interactions but also, and equally important, insights into the molecular make-up of melanoma in its different stages of progression.
The pursuit of genomic studies involving melanoma tissues is a considerable challenge as resected tumors, in particular melanomas in the metastatic growth phase (MGP melanomas), are not only heavily pigmented but often also very necrotic. For this reason, molecular studies of this disease have largely been conducted with cell lines established from primary melanomas in the vertical growth phase (VGP melanomas) and MGP melanomas. However, the picture is changing, and high-throughput genomic approaches are starting to make inroads into the molecular characterization of advanced-stage melanocytic lesions. For example, data from a recently conducted 10K microarray analysis of RNAs isolated from VGP melanomas and MGP melanoma-positive lymph nodes (McDonald et al., 2004) demonstrated that the largest biological category of genes, detected in the VGP melanomas, was comprised of housekeeping genes, followed by genes of unknown function, genes involved in immune response and transcription factors. In the case of the MGP melanoma-infiltrated lymph nodes, the largest biological categories of genes encompassed housekeeping genes, followed by genes governing immune responses, genes with unknown functions and genes regulating cellular metabolism. Interestingly, these results are similar to those reported for another melanoma tissue-based DNA microarray study (Wang et al., 2004) , which showed that genes associated with cellular metabolism and immune responses are expressed at high levels in MGP melanomas and MGP melanoma-infiltrated lymph nodes. These findings, as well as data obtained in the context of Serial Analysis of Gene Expression (SAGE) studies (Smith et al., 2004; , gave strong indications that the molecular profiles of VGP and MGP melanomas are similar. This observation has been further substantiated by the results of a recently conducted whole-genome expression profiling project (Smith et al., 2005) , which provided the first evidence for the existence of two distinct molecular profiles governing the melanoma progression pathway -one that is specific for and encompasses benign and atypical nevi and melanomas in situ, and the other, encompassing VGP and MGP melanomas, and MGP melanomapositive lymph nodes. Although the data of these highthroughput genomic studies convey the same message, namely that the molecular signature of VGP and MGP melanomas is essentially indistinguishable, the melanoma tumor-node-metastasis staging system (Balch et al., 2000 (Balch et al., , 2004 uses as one of its important staging criteria, the absence or presence of micro-or macro-metastases in lymph nodes. Thus, we wanted to determine whether genes and proteins could be identified that are predominantly or exclusively expressed in MGP melanomainfiltrated lymph nodes, and at high levels.
To identify genes with known and unknown functions that hitherto have not been shown to be expressed in MGP melanoma-infiltrated nodes, we generated a LongSAGE library from a melanoma-positive lymph node tissue specimen and, in parallel, subjected protein lysates from resected lymph nodes to antibody array analysis. The results of these studies demonstrate that the distribution by biological function of transcripts identified in the LongSAGE lymph node library is not different from the ones reported for VGP and MGP melanoma SAGE libraries (Smith et al., 2004) . Equally important, the antibody array study identified the SUMO E2-conjugating enzyme, Ubc9, as the highest expressed protein in the melanoma-infiltrated lymph nodes, and we provide data, which demonstrate that Ubc9 is an important player in the response of melanoma cells to cytotoxic drugs.
Results
Genes identified in a melanoma-positive lymph node LongSAGE library As the LongSAGE technique (Saha et al., 2002) generates 17-21 bp tags, which allow a more specific tag-to-gene assignment than the 10-14 bp tags obtained by the original SAGE method (Velculescu et al., 1995) , we generated a LongSAGE library from a melanomapositive lymph node. The portion of this LongSAGE library, termed LYN1, which was sequenced, contained 3160 tags. SAGE 2000 software, version 4.5, was used to extract the tags from the sequence file and analyse them. By comparing the SAGE tag sequences to all sequences available in the UniGene database, 780 cDNA sequences represented known genes, 249 cDNA sequences corresponded to transcripts with unknown functions and 282 cDNA sequences had no available UniGene number. The distribution of the identified transcripts by the biologic function is displayed in Figure 1 and the individual genes/transcripts that are present in LYN1 with a tag count of X15 are listed in Table 1 . Although the number of tags, contained in the part of the LYN1 LongSAGE library that was sequenced, was only about one-tenth of the number of tags that constituted previously generated VGP (DB1; DB2) and MGP melanoma SAGE libraries (DB3; DB4) (Smith et Figure 1 Distribution by biological function of transcripts identified in the melanoma-positive lymph node LongSAGE library, LYN1. Transcripts with a tag count of X10 were categorized according to biological function, and the percentage of transcripts in each category was determined per total number of categorized transcripts.
2004), the distribution of the LongSAGE tags by biologic category is similar to that in DB1, DB2, DB3 and DB4 (Smith et al., 2004) . Furthermore, a comparison of genes, present in LYN1, to genes that were identified in (i) the VGP and MGP melanoma SAGE libraries; (ii) by 10K gene chip analysis of VGP melanomas and MGP melanoma-infiltrated lymph nodes (McDonald et al., 2004) and (iii) a recently conducted nevus and melanoma tissue-based wholegenome microarray analysis (Smith et al., 2005) revealed a significant number that are the same. Apart from the S100 antigen, they are, to name a few of them, osteopontin, interferon alpha-inducible protein, kangai (CD82 antigen), apolipoprotein D and E and integrins (a and b subunits).
Antibody array analysis reveals high-level expression of the SUMO E2-conjugating enzyme, Ubc9, in melanomainfiltrated lymph nodes As the portion of the melanoma-lymph node Long-SAGE library, which was sequenced, identified a significant number of genes that were previously also identified by SAGE and DNA expression profiling of VGP and MGP melanomas, we did not proceed with the sequencing of the remainder of the LYN1 LongSAGE library. Instead, to determine whether we could identify proteins, which by virtue of being expressed at high levels may play an important role in the biological process of melanoma cells metastasizing to and infiltrating regional lymph nodes, we prepared total cell lysates from eleven MGP melanoma-positive lymph nodes. Because we were interested in obtaining molecular profiles of the entire composition of cells present in melanoma-infiltrated lymph nodes, we did not use Laser Capture Microdissection to dissect out the lymphocytes before the antibody array analysis. However, we did exclude small areas in the lymph nodes that by H&E analysis were found to be non-viable (necrotic). Upon labeling with the fluorochrome, Cy3, the proteins were hybridized to an antibody array (BD Clontech Antibody (Ab) Microarray 500; BD Biosciences Clontech, Mountain View, CA, USA). The raw signal intensity data were processed with SpotFinder software, and analysed with the Limma bioinformatics program (BioConductor).
The results of the antibody array analysis identified Ubc9/UBE2I (Wang et al., 1996a; Watanabe et al., 1996; Yasugi and Howley, 1996) as the most highly expressed protein in the eleven arrayed MGP melanoma-infiltrated lymph nodes ( Table 2 ). The enzyme Na þ /K þ ATPase, an integral membrane protein, was the second highest expressed protein, followed by the TNF receptor-associated factor 2 , b-tubulin and others. The protein, expressed at the lowest level in all eleven MGP melanoma-positive lymph nodes was G protein-coupled receptor kinase interactor 1 (data not shown), which is a GTPase-activating protein for the ADP ribosylation factor (ARF) family of small GTPbinding proteins (Premont et al., 1998) . To independently verify that Ubc9 was indeed highly expressed in MGP melanoma-positive lymph nodes, and to determine pattern and level of Ubc9 expression in the melanoma progression pathway, we probed cryopreserved tissue specimens, ranging from normal skin to MGP melanomas as well as nevus-melanoma progression tissue microarrays (TMAs) containing 181 tissue cores, with an antibody to human Ubc9 (hUbc9). As depicted in Figure 2a and b, Ubc9 is strongly expressed in epidermal keratinocytes and dermal fibroblasts of normal skin, in the epidermis and dermal components of nevi, in cells representing melanoma in situ, in almost every VGP melanoma cell, and confirming the findings from the antibody array analysis, very strongly in virtually every melanoma cell of melanoma-infiltrated lymph nodes.
Furthermore, reverse-transcriptase-polymerase chain reaction analysis of human melanoma cell lines with primers specific for the 5 0 and 3 0 end of the full-length human Ubc9 cDNA (Wang et al., 1996a) , generated a 1.8 kb cDNA fragment (data not shown), and immunoblot analysis of melanoma cell lysates, probed with an antibody to Ubc9, revealed the presence of the 17 kDa Ubc9 protein in all melanoma cell lines analysed (data not shown).
Inhibition of Ubc9 expression impairs melanoma cell proliferation but not their cell cycle regulation To gain insights into the possible function(s) of Ubc9 in advanced-stage melanomas, we used Ubc9-specific small interfering RNAs (siRNAs) to inhibit its expression in established MGP melanoma cell lines. The results of immunoblot analyses of Ubc9 siRNA-transfected MGP melanoma cells, are displayed in Figure 3A which demonstrate prominent downregulation of Ubc9 as early as 48 h following transfection. Because we noted that melanoma cells transfected with Ubc9 siRNAs appeared to proliferate at a lower rate compared to control siRNA-transfected melanoma cells, we labeled MGP melanoma cells with the dye, carboxyfluorescein diacetate succinimidyl ester (CFSE), before plating and transfection with a Ubc9 siRNA (Lin et al., 2003) . Subsequent flow cytometric analysis of the CFSE-labeled cells demonstrated that starting at 72 h, and becoming most pronounced at 120 h post-transfection, the Ubc9 siRNA-transfected cells revealed a substantial decrease in proliferation compared to the controls, which included MGP melanoma cells that received only lipofectamine, or enhanced Green Fluorescent Protein (eGFP)-specific siRNA ( Figure 3B ). On the other hand, the same MGP melanoma cells, labeled with propidium iodide and transfected with the same Ubc9 siRNA, did not demonstrate significant deregulation of their cell cycle progression ( Figure 3C ).
Ubc9 expression prevents melanoma cell apoptosis
Because we also observed that in addition to proliferating at a lower rate, the Ubc9 siRNA-transfected melanoma cells revealed morphological changes indicative of apoptosis ( Figure 4A, panel c) ; we subjected the cells to TdT-mediated dUTP nick end labeling (TU-NEL) staining. Compared to melanoma cells transfected with control RISC-Free siRNA, which showed the presence of some apoptotic cells ( Figure 4B, panel a) , the Ubc9 siRNA-transfected melanoma cells demonstrated a significantly larger number of apoptotic cells ( Figure 4B, panel b) . The latter finding prompted us to determine whether the extent of the Ubc9 targetinginduced apoptosis could be augmented by adding the cytotoxic drug, cisplatin, to the siRNA-transfected melanoma cells. The phenotypic changes of the Ubc9 siRNA/cisplatin-treated melanoma cells provided a first indication that this may be the case ( Figure 4C, panel c) . Furthermore, probing them with an antibody to the activated form of the H2A histone family member, H2A.X, revealed compared to the controls ( Figure 4D , panels a-c), a markedly increased expression of yH2A.X ( Figure 4D, panel d) , which is rapidly phosphorylated at serine 139 in response to DNA damage or apoptosisinducing agents. Following these initial findings, we then labeled the cells with Annexin V/propidium iodide, and subjected them to flow cytometric analysis. As depicted in Figure 5a , the flow cytometry data demonstrated that approximately 35% of Ubc9 siRNA-transfected melanoma cells underwent programmed cell death, and that this increased to 70% when, in addition, the cells were incubated for 24 h in the presence of cisplatin. To investigate whether this massive onset of melanoma cell apoptosis was specific for the combination of blocking Ubc9 and adding cisplatin, or whether this would also occur when combined with other chemotherapy agents, we added paclitaxel and likewise, temozolomide to Ubc9 siRNA-transfected melanoma cells. incubated in the presence of paclitaxel for 24 h, 70% of the Annexin V/propidium iodide-stained cells were found to be apoptotic (Figure 5b ). On the other hand, Ubc9 siRNA-transfected melanoma cells exposed to temozolomide did not exhibit a major increase in the number of apoptotic cells when compared to melanoma cells that received Ubc9 siRNAs but not the cytotoxic drug (Figure 5c ). 
Discussion
As the sentinel lymph node (SLN) status is the most powerful prognostic factor in stage I and II melanoma patients (Balch et al., 2000 (Balch et al., , 2004 , SLN mapping and biopsy have become important staging tools, codified in the American Joint Committee on Cancer (AJCC) staging system, to determine whether regional lymph nodes of a melanoma patient are cancer-free or not. Hence, it is surprising that this has not spurred initiatives to identify genes that govern important functions in melanoma-infiltrated lymph nodes, and equally important, to assess whether the molecular signature of regional lymph nodes resembles the genetic profile of VGP melanomas, and/or subcutaneous and visceral metastases. To gain insights into the molecular profile of melanoma-infiltrated nodes, we constructed a Long-SAGE library from a melanoma-positive lymph node. Comparison of the genes identified in the sequenced portion of this library to the genes identified in previously generated melanoma SAGE libraries (Smith et al., 2004) , and by gene chip analysis (McDonald et al., 2004; Smith et al., 2005) , revealed quite a few that are the same. In addition to tags, corresponding to genes such as major histocompatibility complex, class I and II antigens, and interferon alpha-inducible proteins, other genes present in the LYN1 LongSAGE library that were also detected in melanoma SAGE libraries DB1, DB2, DB3, DB4 and/or by microarray analyses of melanoma tissues, were kangai (KAI1), also known as CD82 antigen, coiled-coil-helix-coiled-coil-helix domain containing 2 (CHCHD2), a gene with unknown function, integrins and osteopontin. The finding that osteopontin, also termed SPP1, is expressed in LYN1, is specifically noteworthy in light of our recently conducted wholegenome microarray analysis, which revealed that osteopontin leads the list of the top 50 genes that are upregulated concordant with the progression from melanoma in situ to VGP melanoma (Smith et al., 2005) .
hUbc9, following its isolation (Wang et al., 1996a; Watanabe et al., 1996; Yasugi and Howley, 1996) as a homolog of the yeast ubiquitin-conjugating enzyme, ScUbc9 (Seufert et al., 1995) has been shown to govern important functions in mammalian cells by way of its interaction with genes such as the human p14 (Rizos et al., 2005) and mouse p19ARF tumor suppressor (Tago et al., 2005) , the DNA repair protein, Rad51 (Kovalenko et al., 1996) , the microphthalmia transcription factor, MITF (Xu et al., 2000) and Smad4 (Lin et al., 2003) . Unlike ubiquitination, which targets proteins for degradation, sumoylation stabilizes target proteins, and as Ubc9 is the only E2-conjugating enzyme required for protein sumoylation, it has a central function in major biological processes such as DNA damage repair (Hoege et al., 2002) , nuclear integrity and chromosome segregation (Nacerddine et al., 2005) , and as shown in Saccharomyces cerevisiae, progression through mitosis (Johnson and Blobel, 1997) . On the other hand, an indication that Ubc9 may play a role in mammalian cell apoptosis has so far only been deduced from its interaction with p53 (Rodriguez et al., 1999; Lin et al., 2004) , and the Fas-associated protein, Daxx (Mo et al., 2004) .
The data reported here are the first to show that Ubc9 plays a crucial role in preventing melanoma cell apoptosis. Furthermore, of the substantial number of genes whose functions in advanced-stage melanomas have been determined over the past two decades (for reviews, see Perlis and Herlyn, 2004; Herlyn, 2006) , we find that Ubc9 is the second gene that, like fibroblast growth factor receptor 1 , when blocked in its expression (Wang and Becker, 1997; Valesky et al., 2002) , drives melanoma cells into massive apoptosis. Although it is somewhat surprising that we identified Ubc9 as the most prominently expressed gene in melanoma-infiltrated lymph nodes by antibody but not whole-genome array profiling (Smith et al., 2005) , the fact that Ubc9 is expressed at high levels in tissues representing every stage of the melanoma progression pathway (Figure 2a and b), strongly indicates that this gene and its encoded protein have an essential function(s) in the biology of this disease. Equally important, we provide first-time evidence that inhibiting Ubc9 expression sensitizes melanoma cells in a major fashion to the action of chemotherapeutic drugs, which are normally not effective as part of standard care chemotherapy regimens for patients with unresectable, locally advanced or stage IV melanoma. Although none of the three chemotherapeutic agents we added to MGP melanoma cultures following their transfection with Ubc9 or control RISCFree siRNAs, requires metabolic activation by cytochrome P450, it is interesting to note that cisplatin and paclitaxel augmented Ubc9 targeting-induced melanoma cell apoptosis by as much as 50%, but temozolomide by only 10-15%. A possible explanation for the comparatively lower efficacy of temozolomide on the Ubc9 siRNA-transfected melanoma cells may be that, unlike cisplatin, which acts by cross-linking DNA, and paclitaxel, which disrupts the balance between tubulin and microtubule fibers, temozolomide needs to be converted, at physiologic pH, to the metabolite monomethyl triazeno imidazole carboxamide, which then alkylates DNA at guanine nucleotides -a process that may not be very effective in melanoma cells. Another observation of importance to point out in the context of these findings is the fact that we did not observe substantial accumulation of the Ubc9-targeted melanoma cells in G1/S or G2/M phase ( Figure 3C ), which as previously postulated (Hayashi et al., 2002) , may suggest that in Ubc9-suppressed cells, apoptosis is triggered without activating the mitotic checkpoint. Because the data presented here implicate Ubc9 as a major regulator or guardian that prevents melanoma cells from undergoing apoptosis, we are presently conducting studies to assess whether in the setting of a preclinical model, blocking expression of Ubc9 causes growth arrest of human melanoma xenografts and/or prevents the development of advanced-stage melanomas. Our second objective is to obtain information regarding molecules and signal transduction pathways that are affected in response to suppressing Ubc9 expression/function(s) in VGP and MGP melanomas in both the absence and presence of chemotherapy agents, such as cisplatin and/or paclitaxel. Although based upon the data presented here, it is not unreasonable to suggest that it is primarily the apoptosis pathway that is deregulated as a result of downregulating Ubc9 expression in melanomas, we cannot rule out that an additional signaling pathway(s) may prevent the cells from undergoing programmed cell death. For example, as part of preliminary investigations along this line, we observed that upon inhibiting Ubc9 expression, total and phosphorylated STAT1 (at Tyr701) are upregulated in MGP melanoma cells (data not shown), which is in agreement with the finding that STAT1 is subject to SUMO-1 conjugation (Ungureanu et al., 2003) . On the other hand, some of these preliminary results differ from previous findings (Tashiro et al., 1997; Xu et al., 2000; Mo et al., 2005) , in that we do not detect overt differences in levels of expression of the transcription factor, MITF, the NF-kappa B (NF-kB) inhibitor, IkBa, or the apoptosis suppressor, bcl-2. In summary, the results of our LongSAGE and antibody array analyses, presented here, provide a detailed molecular view of melanoma-infiltrated lymph nodes, and identify the SUMO E2-conjugating enzyme as a key molecule in melanoma cell metastasis and evasion of apoptosis. Follow-up studies are to assess and determine whether Ubc9 may serve as a valuable new target for melanoma therapy, or whether, given its central role in SUMO modification of proteins, it may be preferable to target downstream effectors of Ubc9 as a means to drive melanoma cells into apoptosis. At the same time, further emphasis on efforts leading to the identification of additional proteins that, in melanomas, are subject to sumoylation, may guide us towards an understanding of SUMO-dependent processes, regulating melanoma resistance to chemotherapy.
Materials and methods
Tissue collection and histologic evaluation Melanoma-infiltrated lymph nodes were obtained from patients with stage IIIB and IIIC palpable regional lymphadenopathy, who had not undergone systemic treatment for their disease before surgical resection of the lymph nodes. Likewise, nevus, melanoma in situ, VGP and visceral and subcutaneous MGP melanoma tissue specimens were obtained from patients with a clinical history of melanoma, who had not undergone systemic treatment for their disease before surgical resection of the lesions. Tissue specimens, representing normal skin, were obtained from patients with no clinical history of melanoma. All tissues were collected in compliance with approved clinical protocols (University of Pittsburgh Cancer Institute (UPCI) protocols 96-039, 96-099 and 99-088; Institutional Review Board (IRB) protocols 960712, 970186 and 000629). The degree of architectural and cytologic atypia of the nevus and melanoma tissue specimens was determined by histopathological analysis of their formalin-fixed and paraffin-embedded parts. Hematoxylin and eosin and where applicable, S100 antibody-stained tissue sections, prepared from the snapfrozen part of each specimen, were analysed to validate their histology.
Construction and analysis of a melanoma-infiltrated lymph node LongSAGE library Fifty micrograms of total RNA, isolated with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) from an MGP melanomapositive lymph node were used to generate a LongSAGE library with the I-SAGE Long Kit (Invitrogen). Modifications, made to the LongSAGE protocol, included extended incubation times for restriction enzyme digestions, and longer ligation periods to enhance cDNA adaptor and ditag formation. Transformants were screened by colony PCR. Clones, containing inserts of sufficient length, were sequenced by Agencourt Bioscience Corporation (Beverly, MA, USA). LongSAGE tags were extracted from the sequence file, and analysed with SAGE 2000 software, version 4.5. UniGene tagto-gene assignment was performed using the LongSAGE SAGEmap database available at the time of analysis (http:// www.ncbi.nlm.nih.gov/SAGE). The portion of the Long-SAGE library, which was sequenced, yielded 3160 tags.
Antibody array profiling and bioinformatics analysis
In the case of each melanoma-positive lymph node, total cell lysate was prepared from 20 mg of snap-frozen tissue, using a protein extraction and labeling kit (BD Biosciences Clontech, Mountain View, CA, USA). Cy3-labeled proteins were hybridized to the BD Clontech Antibody Microarray 500 (BD Biosciences Clontech) as per the manufacturer's recommendation, and slides were scanned at 532 nm on a GenePix 4000B array scanner (Molecular Devices Corporation, Sunnyvale, CA, USA). Post-scanning raw signal intensity data of the label-based antibody arrays were processed with TIGR SpotFinder v2.2.3 software to extract the spot intensities expressed in the log 2 scale, which were then analysed with Limma 1.9.6 (BioConductor). The background of each image was corrected via log-linear interpolation (Edwards, 2003) , and the betweenarray variation was normalized using the quantile method (Bolstad et al., 2003) . For each protein, average expression across the arrayed lymph node samples (n ¼ 11) was calculated using the robust Tukey's biweight M-estimator. Proteins were ranked according to their level of expression.
Immunohistochemistry of cryopreserved nevus and melanoma tissue specimens and TMA analysis Standard immunohistochemistry of snap-frozen tissue samples, representing the different histological stages of the melanoma progression pathway, was performed as described previously (Wang et al., 1996b) , using a goat anti-human Ubc9 antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Nevus-melanoma progression pathway TMAs were constructed by the National Cancer Institute -Center for Cancer Research (NCI-CCR) Tissue Array Research Program (TARP). Following antigen retrieval, the tissue cores (41 benign and atypical nevi; 46 VGP melanomas, 60 subcutaneous and visceral MGP melanomas and 34 melanomainfiltrated lymph nodes) were probed with the Ubc9-specific antibody using standard immunohistochemistry. The TMAs were obtained from the NCI for beta testing purposes, and the data are included with permission from the NCI.
siRNA transfection and immunoblot analysis Ubc9 SMARTpool siRNAs (100 nM) or 100 nM control RISCFree siRNA (Dharmacon, Lafayette, CO, USA) was mixed with Lipofectamine 2000 (Invitrogen), and transfected into WM1158 MGP melanoma cells (Herlyn et al., 1987) , cultured as previously described (Becker et al., 1989) .
Protein lysates (20 mg/sample), separated on 15% sodium dodecyl sulfate-polyacrylamide gels and transferred onto nylon membrane, were probed with Ubc9 antibody, followed by incubation with a horseradish peroxidase-conjugated secondary antibody, and Luminol reagent (Santa Cruz Biotechnology, Inc.).
Cell proliferation assay, DNA content/cell cycle analysis, TUNEL staining and immunofluorescence MGP melanoma cells were labeled with the dye, CFSE or propidium iodide (Invitrogen) as per the manufacturer's recommendation, plated and either not transfected or transfected with 100 nM of Silencer eGFP siRNA (Ambion/Applied Biosystems, Foster City, CA, USA), or 100 nM of a Ubc9 siRNA (5 0 -CAAAAAATCCCGATGGCAC-3 0 ) (Lin et al., 2003) (Dharmacon). The CFSE-labeled melanoma cells were subjected to flow cytometry at 24, 72 and 120 h post siRNA transfection, and the propidium iodide-labeled cells at 48, 72, 96 and 120 h following siRNA transfection.
Cytospin preparations of MGP melanoma cells not transfected or transfected with 100 nM RISC-Free or 100 nM Ubc9 siRNAs were fixed with paraformaldehyde, and stained using an Apoptag Peroxidase in situ apoptosis detection kit (Chemicon International, Inc., Temecula, CA, USA). The cells were counterstained with methyl green (Vector Laboratories, Burlingame, CA, USA).
MGP melanoma cells not transfected or transfected with 100 nM RISC-Free or 100 nM Ubc9 siRNAs for 4 days, were treated with 20 mM cisplatin for 4 h, and probed with a mouse monoclonal anti-phospho-histone H2A.X (ser139) antibody (Upstate Cell Signaling Solutions, Charlottesville, VA, USA), and a goat anti-mouse Cy5-conjugated secondary antibody (GE Healthcare Life Sciences, Piscataway, NJ, USA). The antibody-probed cells were counterstained with fluorescent 4 0 -6-diamidino-2-phenylindole.
Cytotoxic drug treatment and flow cytometric analysis of apoptosis and necrosis MGP melanoma cells not transfected, or transfected with 100 nM RISC-Free or 100 nM Ubc9 siRNAs were cultured, starting on day 4 post-siRNA transfection, in the presence of cisplatin (20 mM for 24 h), paclitaxel (20 mM for 12 h) or temozolomide (1 mM for 24 h). Thereafter, the cells were resuspended in phosphate-buffered saline, and stained using an Alexa Fluor 488 Annexin V/propidium iodide kit (Vybrant apoptosis assay kit #2 (Invitrogen)). The stained cells were analysed by flow cytometry, measuring fluorescence emission at 530 and >575 nm. Ten thousand gated events were collected, and analysed with EXPO32 flow cytometry software (Beckman Coulter, Inc., Fullerton, CA, USA). Two independent experiments/flow cytometric analyses were conducted in the case of cisplatin, paclitaxel and temozolomide treatment.
